These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17364080

  • 1. The use of biological agents in the treatment of rheumatoid arthritis.
    Fan PT, Leong KH.
    Ann Acad Med Singap; 2007 Feb; 36(2):128-34. PubMed ID: 17364080
    [Abstract] [Full Text] [Related]

  • 2. [New ways in the management of rheumatoid arthritis in Hungary].
    Gergely P, Poór G.
    Lege Artis Med; 2007 Oct; 17(10):657-64. PubMed ID: 19227595
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis.
    Venkateshan SP, Sidhu S, Malhotra S, Pandhi P.
    Pharmacology; 2009 Oct; 83(1):1-9. PubMed ID: 18957873
    [Abstract] [Full Text] [Related]

  • 4. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Oct; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 5. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J.
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [Abstract] [Full Text] [Related]

  • 6. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
    Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH.
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
    [Abstract] [Full Text] [Related]

  • 8. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F.
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [Abstract] [Full Text] [Related]

  • 9. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scirè CA.
    BMJ Open; 2018 Sep 11; 8(9):e021447. PubMed ID: 30206082
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.
    Clin Exp Rheumatol; 2013 Sep 11; 31(3):400-8. PubMed ID: 23464803
    [Abstract] [Full Text] [Related]

  • 11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 11; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 12. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
    Liao TL, Chen YM, Liu HJ, Chen DY.
    BMJ Open; 2017 Jan 05; 7(1):e014032. PubMed ID: 28057661
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA.
    Curr Opin Rheumatol; 2007 May 05; 19(3):308-13. PubMed ID: 17414961
    [Abstract] [Full Text] [Related]

  • 14. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr 05; 30(178):289-94. PubMed ID: 21595177
    [Abstract] [Full Text] [Related]

  • 15. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
    Papagoras C, Voulgari PV, Drosos AA.
    Autoimmun Rev; 2010 Jun 05; 9(8):574-82. PubMed ID: 20433955
    [Abstract] [Full Text] [Related]

  • 16. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU, Burmester GR.
    Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract] [Full Text] [Related]

  • 17. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov 13; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 18. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N.
    Cytokine; 2018 Jan 13; 101():56-63. PubMed ID: 27567553
    [Abstract] [Full Text] [Related]

  • 19. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model].
    Brodszky V.
    Orv Hetil; 2011 Jun 05; 152(23):919-28. PubMed ID: 21592952
    [Abstract] [Full Text] [Related]

  • 20. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT.
    Drugs; 2009 Oct 22; 69(15):2035-43. PubMed ID: 19791825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.